Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal

A randomized Phase III trial evaluating iniparib (BSI-201) in patients with metastatic triple-negative breast cancer (mTNBC) did not meet the pre-specified criteria for significance for co-primary endpoints of overall survival and progression-free survival......

Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal